Jiang et al., in a genome-wide association study of 5222 PCa patients, found that an inherited MROH1 variant (or single nucleotide polymorphism, SNP) was one of the genetic factors that would warrant conversion of management strategies from active surveillance to treatment [78]. This evidence concerns the gene MROH1 and posterior cortical atrophy.